{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:09:23Z","timestamp":1788930563741,"version":"build-2803163510"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    Second primary cancers (SPCs) are an important challenge in cancer survivorship, yet their heterogeneous biological origins cannot be reduced to treatment exposure. Inherited susceptibility shared environmental and tissue-field effects, ageing, pre-existing somatic mosaicism and treatment-associated mutagenesis contribute to SPC risk. High-resolution studies show that therapy can alter somatic selection, clonal architecture and persistent immune or stromal states in normal tissues. We propose the therapy-conditioned host as a State-Transition framework integrating these observations in survivorship. In this framework, a pre-treatment host state (H\n                    <jats:sub>0<\/jats:sub>\n                    ) is perturbed by therapy (P), generating evolving post-treatment states H(t), defined by interacting genomic, clonal, immune and stromal\/tissue features. H(t) describes biological state at time t, whereas the sequence H\n                    <jats:sub>0<\/jats:sub>\n                    \u2192H(t\n                    <jats:sub>1<\/jats:sub>\n                    )\u2192H(t\n                    <jats:sub>2<\/jats:sub>\n                    )\u2026 defines the host trajectory. Equivalent exposures may generate different trajectories, while distinct treatments may converge on similar biological states. Treatment history is therefore an imperfect proxy for biological consequence. The framework does not imply that all SPCs are therapy-induced, that post-treatment conditioning is inherently carcinogenic, or that clonal expansion is equivalent to malignant progression. It proposes that the magnitude, direction and persistence of treatment-associated changes may influence the evolutionary opportunities of normal and premalignant cells. We outline testable predictions and a translational pathway requiring longitudinal validation, incremental predictive value beyond baseline susceptibility and treatment history, clinical actionability and evidence that intervention improves outcomes without disproportionate harm. The central question is not only what treatment a survivor received, but what biological state it produced, how that state evolves over time, and whether its trajectory meaningfully alters subsequent cancer risk.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2026.1966473","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T04:43:59Z","timestamp":1788929039000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The therapy-conditioned host: a state-transition framework for second primary cancer evolution"],"prefix":"10.3389","volume":"16","author":[{"given":"Rosiane Batista","family":"Mastelari","sequence":"first","affiliation":[{"name":"University Hospital, Federal University of Pelotas - HUBrasil","place":["Pelotas, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago Veiras","family":"Collares","sequence":"additional","affiliation":[{"name":"University Hospital, Federal University of Pelotas - HUBrasil","place":["Pelotas, Brazil"]},{"name":"Postgraduate Program in Biotechnology, Center for Technological Development, Federal University of Pelotas","place":["Pelotas, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00538-7","article-title":"Cumulative incidence of second primary cancers in a large nationwide cohort of Danish cancer survivors: a population-based retrospective cohort study","volume":"25","author":"Kjaer","year":"2024","journal-title":"Lancet Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00157-3","article-title":"Contributions of cancer treatment and genetic predisposition to risk of subsequent neoplasms in long-term survivors of childhood cancer: a report from the St Jude Lifetime Cohort and the Childhood Cancer Survivor Study","volume":"26","author":"Neupane","year":"2025","journal-title":"Lancet Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02837-7","article-title":"Polygenic risk scores, radiation treatment exposures and subsequent cancer risk in childhood cancer survivors","volume":"30","author":"Gibson","year":"2024","journal-title":"Nat Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.0286","article-title":"Second primary breast cancer in young breast cancer survivors","volume":"10","author":"Brantley","year":"2024","journal-title":"JAMA Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-1186","article-title":"Origins of second Malignancies in children and mutational footprint of chemotherapy in normal tissues","volume":"14","author":"S\u00e1nchez-Guix\u00e9","year":"2024","journal-title":"Cancer Discov"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-09792-4","article-title":"Somatic evolution following cancer treatment in normal tissue","volume":"653","author":"Pich","year":"2026","journal-title":"Nature"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-025-02234-x","article-title":"The long-term effects of chemotherapy on normal blood cells","volume":"57","author":"Mitchell","year":"2025","journal-title":"Nat Genet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-025-02235-w","article-title":"Clonal evolution of hematopoietic stem cells after autologous stem cell transplantation","volume":"57","author":"Uryu","year":"2025","journal-title":"Nat Genet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41586-024-07882-3","article-title":"Mechanisms that clear mutations drive field cancerization in mammary tissue","volume":"633","author":"Ciwinska","year":"2024","journal-title":"Nature"},{"key":"B10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/nrc.2017.102","article-title":"An evolutionary perspective on field cancerization","volume":"18","author":"Curtius","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1126\/science.aau3879","article-title":"Somatic mutant clones colonize the human esophagus with age","volume":"362","author":"Martincorena","year":"2018","journal-title":"Science"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0811-x","article-title":"Age-related remodelling of oesophageal epithelia by mutated cancer drivers","volume":"565","author":"Yokoyama","year":"2019","journal-title":"Nature"},{"key":"B13","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1126\/science.aba8347","article-title":"Extensive heterogeneity in somatic mutation and selection in the human bladder","volume":"370","author":"Lawson","year":"2020","journal-title":"Science"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-08708-6","article-title":"The somatic mutation landscape of normal gastric epithelium","volume":"640","author":"Coorens","year":"2025","journal-title":"Nature"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-1961-1","article-title":"Tobacco smoking and somatic mutations in human bronchial epithelium","volume":"578","author":"Yoshida","year":"2020","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","first-page":"5915","DOI":"10.1038\/s41467-022-33663-5","article-title":"Common anti-cancer therapies induce somatic mutations in stem cells of healthy tissue","volume":"13","author":"Kuijk","year":"2022","journal-title":"Nat Commun"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-019-0525-5","article-title":"The mutational footprints of cancer therapies","volume":"51","author":"Pich","year":"2019","journal-title":"Nat Genet"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-25-0231","article-title":"Therapy-related mutational signatures in subsequent neoplasms among survivors of childhood cancer","volume":"16","author":"Brady","year":"2026","journal-title":"Cancer Discov"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-026-10803-1","article-title":"Prior therapy defines mutation profiles in childhood cancer at relapse","author":"Layeghifard","year":"2026","journal-title":"Nature"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-09584-w","article-title":"Somatic mutation and selection at population scale","volume":"647","author":"Lawson","year":"2025","journal-title":"Nature"},{"key":"B21","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41586-026-10386-x","article-title":"Tumour promotion through the lens of evolution","volume":"652","author":"L\u00f3pez-Bigas","year":"2026","journal-title":"Nature"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-020-00710-0","article-title":"Cancer therapy shapes the fitness landscape of clonal hematopoiesis","volume":"52","author":"Bolton","year":"2020","journal-title":"Nat Genet"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-0956","article-title":"Dynamics of age- versus therapy-related clonal hematopoiesis in long-term survivors of pediatric cancer","volume":"13","author":"Hagiwara","year":"2023","journal-title":"Cancer Discov"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-026-02526-w","article-title":"CDK4\/6 inhibition mitigates chemotherapy-induced expansion of TP53-mutant clonal hematopoiesis","volume":"58","author":"Chan","year":"2026","journal-title":"Nat Genet"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1126\/science.adx4174","article-title":"Inherited resilience to clonal hematopoiesis by modifying stem cell RNA regulation","volume":"391","author":"Agarwal","year":"2026","journal-title":"Science"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0497-0","article-title":"Population dynamics of normal human blood inferred from somatic mutations","volume":"561","author":"Lee-Six","year":"2018","journal-title":"Nature"},{"key":"B29","doi-asserted-by":"publisher","first-page":"9286","DOI":"10.1038\/s41467-024-53295-1","article-title":"Epigenetic memory of radiotherapy in dermal fibroblasts impairs wound repair capacity in cancer survivors","volume":"15","author":"Bian","year":"2024","journal-title":"Nat Commun"},{"key":"B30","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/s41416-022-01792-9","article-title":"Anti-cancer therapy is associated with long-term epigenomic changes in childhood cancer survivors","volume":"127","author":"Robinson","year":"2022","journal-title":"Br J Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1038\/s41467-024-46769-9","article-title":"Senescence drives immunotherapy resistance by inducing an immunosuppressive tumor microenvironment","volume":"15","author":"Maggiorani","year":"2024","journal-title":"Nat Commun"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41556-026-02025-4","article-title":"Stromal cell senescence augments haematopoietic cell fitness in clonal haematopoiesis","volume":"28","author":"Mistry","year":"2026","journal-title":"Nat Cell Biol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-3886","article-title":"The impact of immunotherapy on incidence of second primary Malignancies: A surrogate for antitumor surveillance activation","volume":"32","author":"Adcock","year":"2026","journal-title":"Clin Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.57807","article-title":"Development of secondary cancers in pre- vs post-ICI eligibility periods for metastatic cancers","volume":"9","author":"Li","year":"2026","journal-title":"JAMA Netw Open"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30360-4","article-title":"Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective WHO pharmacovigilance study","volume":"8","author":"Morice","year":"2021","journal-title":"Lancet Haematol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401361","article-title":"Risk of second tumors and T-cell lymphoma after CAR T-cell therapy","volume":"390","author":"Hamilton","year":"2024","journal-title":"N Engl J Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03458-w","article-title":"T-cell Malignancies after CAR-T cell therapy in the DESCAR-T registry","volume":"31","author":"Dul\u00e9ry","year":"2025","journal-title":"Nat Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0209-6","article-title":"The pro-tumorigenic host response to cancer therapies","volume":"19","author":"Shaked","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-026-02946-x","article-title":"Pre-diagnostic clonal hematopoiesis of indeterminate potential among patients with a primary cancer and risk of second cancers","volume":"40","author":"Liu","year":"2026","journal-title":"Leukemia"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaf181","article-title":"Clonal hematopoiesis and risk of nonmyeloid subsequent Malignant neoplasms after autologous hematopoietic cell transplantation","volume":"117","author":"Rhee","year":"2025","journal-title":"J Natl Cancer Inst"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2025.287422","article-title":"Clinical decisions in clonal hematopoiesis: a contemporary review for clinicians","volume":"111","author":"Vanner","year":"2026","journal-title":"Haematologica"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/sim.9336","article-title":"Landmarking 2.0: Bridging the gap between joint models and landmarking","volume":"41","author":"Putter","year":"2022","journal-title":"Stat Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyab047","article-title":"Reflection on modern methods: Dynamic prediction using joint models of longitudinal and time-to-event data","volume":"50","author":"Andrinopoulou","year":"2021","journal-title":"Int J Epidemiol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwm324","article-title":"Immortal time bias in pharmacoepidemiology","volume":"167","author":"Suissa","year":"2008","journal-title":"Am J Epidemiol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3390\/epidemiologia4020012","article-title":"Screening and surveillance bias in cancer","volume":"4","author":"Tancredi","year":"2023","journal-title":"Epidemiologia"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1966473\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T04:44:04Z","timestamp":1788929044000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1966473\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":46,"alternative-id":["10.3389\/fonc.2026.1966473"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1966473","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"article-number":"1966473"}}